The treatment success rate for multidrug-resistant tuberculosis (MDR-TB) patients in the US is forecasted to increase slightly from 74% in 2024 to 75% by 2025, with this rate remaining steady through 2028. In 2023, the actual success rate was 73%, showing a slight improvement in the forecast period.
Year-on-year analysis indicates a modest 1% increase expected from 2023 to 2024 and maintaining stability through 2028. The compound annual growth rate (CAGR) over the next five years suggests a minimal average annual increase.
Future trends to watch for include advances in treatment strategies, potential drug developments, and healthcare policy changes that could influence success rates. Monitoring emerging technologies and research in personalized medicine might significantly impact MDR-TB treatment success rates.
